| 序号 | 修订前条文 | 修订后条文 | | --- | --- | --- | | 1 | 全文：股东大会 | 全文：股东会 | | 2 | 第八条 经理为公司的法定代表 | 第八条 董事长为公司的法定代表人。 | | | 人。 第十四条 许可项目：饲料生产； | 第十四条 许可项目：饲料生产；饲料添加 | | | 饲料添加剂生产；兽药生产；兽 药经营。(依法须经批准的项目， 经相关部门批准后方可开展经 | 剂生产；兽药生产；兽药经营；卫生用品 和一次性使用医疗用品生产；消毒剂生产 （不含危险化学品）。（依法须经批准的项 | | | 营活动，具体经营项目以相关部 | 目，经相关部门批准后方可开展经营活动， | | | 门批准文件或许可证件为准)一 | 具体经营项目以相关部门批准文件或许可 | | 3 | 般项目：粮食收购；鲜肉批发； | 证件为准）一般项目：粮食收购；鲜肉批 | | | 鲜肉零售；食用农产品批发；食 | 发；鲜肉零售；食用农产品批发；食用农 | | | 用农产品零售；饲料原料销售； | 产品零售；饲料原料销售；畜牧渔业饲料 | | | 畜牧渔业饲料销售；饲料添加剂 | 销售；饲料添加剂销 ...

关于召开 2024 年第五次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第五次临时股东大会 召开的日期时间：2024 年 12 月 2 日 13 点 30 分 召开地点：北京市丰台区南四环西路 188 号总部基地 8 区 16 号楼 8 层公司 会议室 股票代码：600195 股票简称：中牧股份 编号：临 2024-052 中牧实业股份有限公司 （五） 网络投票的系统、起止日期和投票时间 股东大会召开日期：2024年12月2日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 12 月 2 日 至 2024 年 12 月 2 日 采用上海证券交易所网络投票系统，通过交 ...

中牧实业股份有限公司 经与会董事审议，会议表决通过如下议案： 一、关于修订《公司章程》部分条款的议案 表决结果：6 票同意，0 票反对，0 票弃权。 同意修订《公司章程》部分条款。具体内容详见《中牧实业股份有限公司关于 修订<公司章程>的公告》（公告编号：临 2024-051）。 本议案需提交公司股东大会审议。 股票代码：600195 股票简称：中牧股份 编号：临 2024-050 第八届董事会 2024 年第二十四次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"或"中牧股份"）第八届董事会 2024 年第二十四次临时会议通知于 2024 年 11 月 12 日通过公司电子办公系统、电子邮 件等形式发出，会议于 2024 年 11 月 15 日以通讯方式召开，会议应出席董事 6 名， 实到董事 6 名。会议由董事长吴冬荀先生主持，符合《公司法》《公司章程》的规 定。 表决结果：6 票同意，0 票反对，0 票弃权。 同意于 2024 年 12 月 2 日召开公司 2024 ...

一、情况概述 股票代码：600195 股票简称：中牧股份 编号：临 2024-049 中牧实业股份有限公司 关于签订《成都市国有土地上房屋搬迁补偿协议》 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、进展情况 特此公告 根据成都市委、市政府关于环城生态区农田整治的工作部署，中牧实业股份 有限公司（以下简称"中牧股份"或"公司"）拟与成都成华棚户区惠民改造建 设有限责任公司（以下简称"成华棚改公司"）签订《成都市国有土地上房屋搬 迁补偿协议》，该事项已经公司第八届董事会 2024 年第二十一次临时会议审议通 过，同意公司与成华棚改公司签订关于成都市成华区蜀陵路 59 号的《成都市国 有土地上房屋搬迁补偿协议》及相关文件，并授权公司管理层操作具体事宜。 中牧实业股份有限公司董事会 具体内容详见公司于 2024 年 10 月 30 日披露的《中牧实业股份有限公司关 于拟签订<成都市国有土地上房屋搬迁补偿协议>的公告》（公告编号：临 2024- 047）。 2024 年 11 月 15 日 2024 年 11 月 1 ...

Investment Rating - The report assigns a "Hold" rating to the company [1][10]. Core Views - The company experienced a slight revenue increase of 0.47% year-on-year, reaching 4.178 billion yuan in the first three quarters of 2024, but faced a significant decline in net profit, down 79.39% to 82 million yuan [1][2]. - In Q3 2024, revenue rose by 2.93% year-on-year to 1.699 billion yuan, while net profit fell by 85.16% to 19 million yuan, indicating challenges in profitability despite stable revenue growth [2][3]. - The company is increasing its R&D investment, which rose by 10.04% year-on-year to 93 million yuan, representing a R&D expense ratio of 2.23% [2][3]. - The company is focusing on expanding its product offerings in the pet health market, which is expected to be a new growth point [3]. Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a revenue of 4.178 billion yuan, a year-on-year increase of 0.47%, and a net profit of 82 million yuan, a decrease of 79.39% [1]. - In Q3 2024, the company reported a revenue of 1.699 billion yuan, up 2.93% year-on-year, and a net profit of 19 million yuan, down 85.16% [2]. R&D and Growth Potential - The company is committed to R&D, with expenses increasing to 93 million yuan, which is expected to enhance product quality and competitiveness in the long term [2][3]. - The approval of a new cat vaccine and advancements in African swine fever vaccine development are notable achievements that may support future growth [2][3]. Market Outlook - The demand for animal health products is anticipated to grow due to increasing awareness of animal health among farming enterprises [3]. - The company is positioning itself in the pet market, which is expected to provide significant growth opportunities [3]. Earnings Forecast - The projected EPS for 2024, 2025, and 2026 is 0.14, 0.37, and 0.52 yuan, respectively, with corresponding dynamic PE ratios of 50, 19, and 13 [3][4].

中牧实业股份有限公司董事会 2024 年 11 月 6 日 附：简历 股票代码：600195 股票简称：中牧股份 编号：临 2024-048 中牧实业股份有限公司 关于总经理辞职暨聘任总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中牧实业股份有限公司（以下简称"公司"）董事会于近日收到吴冬荀先生递交 的书面辞职报告，吴冬荀先生因工作调整，申请辞去公司总经理职务，辞职报告自 送达董事会之日起生效。辞去总经理职务后，吴冬荀先生将继续担任公司第八届董 事会董事长职务。公司及公司董事会对吴冬荀先生在担任公司总经理职务期间为公 司所作出的贡献表示衷心的感谢。 公司于 2024 年 11 月 4 日召开第八届董事会 2024 年第二十二次临时会议，审议 通过了《关于聘任公司总经理的议案》。经公司董事长提名，公司董事会提名委员会 审核通过，公司董事会同意聘任李寅先生为公司总经理（简历详见附件），任期自本 次董事会审议通过之日起至第八届董事会届满之日止。 特此公告 李寅，男，47 岁，中国国籍，无境外永久居留权，硕士研究生学历 ...

Investment Rating - The report maintains a "Recommended" rating for the company [6] Core Views - The company reported a revenue of 4.18 billion yuan for the first three quarters of 2024, a year-on-year increase of 0.5%, and a net profit attributable to shareholders of 80 million yuan, a year-on-year decrease of 79.4% [2] - The decline in net profit is primarily due to falling product prices and a lack of investment income compared to the previous year [2] - The third quarter of 2024 saw a revenue of 1.70 billion yuan, a year-on-year increase of 2.9% and a quarter-on-quarter increase of 25.5%, with a net profit of 20 million yuan, a year-on-year decrease of 85.2% but a quarter-on-quarter turnaround [2] Summary by Sections Upstream and Downstream Performance - The upstream raw material industry remains under pressure due to oversupply and weak downstream demand, leading to low prices for veterinary raw materials [3] - The average price of live pigs in Q3 2024 was 19.5 yuan/kg, a year-on-year increase of 19.5%, which has improved the performance of the downstream animal health sector [3] Cost Management and Profitability - The company has improved its cost management, with a sales expense ratio of 7.5% in Q3 2024, an increase of 0.2 percentage points quarter-on-quarter, while the management expense ratio decreased by 0.9 percentage points to 5.1% [3] - The sales gross margin in Q3 2024 was 16.3%, a quarter-on-quarter increase of 1.2 percentage points but a year-on-year decrease of 3.9 percentage points due to falling product prices [3] Research and Development - The company has increased its R&D investment, with an R&D expense ratio of 2.2% for the first three quarters of 2024, an increase of 0.2 percentage points year-on-year [4] - The company has made progress in its pet segment, receiving approval for a new vaccine for cats, which is expected to enhance its competitiveness in the pet market [4] Financial Forecast - The company is expected to achieve net profits of 311 million yuan, 415 million yuan, and 523 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.30, 0.41, and 0.51 yuan [4][5] - The projected PE ratios for the same years are 22, 17, and 13 times [4][5]

股票代码：600195 股票简称：中牧股份 编号：临 2024-047 中牧实业股份有限公司 关于拟签订《成都市国有土地上房屋搬迁补偿协议》 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次搬迁补偿系政府征收行为，其征收补偿不构成关联交易，亦不构成重 大资产重组，无需提交公司股东大会审议。 一、本次搬迁事项概述 根据成都市委、市政府关于环城生态区农田整治的工作部署，成都市成华区 公园城市建设和城市更新局于 2024 年 3 月 26 日向公司发函《成都市成华区公园 城市建设和城市更新局关于恳请中牧实业股份有限公司支持加快拆迁有关事宜 的函》，由于公司位于成都市成华区蜀陵路 59 号所处位置在拆迁交地范围内，请 公司确保按时完成拆迁交地任务。 按照成都市成华区委、区政府的相关工作安排，成华棚改公司委托四川省天 地房地产土地资产评估有限公司对公司位于成都市成华区蜀陵路 59 号的房地产 进行市场价值评估，并向公司出具了《关于成都市环城生态区蜀陵路 59 号中牧 实业股份有限公司搬迁项目价值评估确认的函 ...

Financial Performance - The company's operating revenue for Q3 2024 was CNY 1,699,007,077.41, representing a year-on-year increase of 2.93%[2] - The net profit attributable to shareholders for Q3 2024 was CNY 18,997,959.60, a decrease of 85.16% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was CNY 19,507,225.32, down 82.38% year-on-year[2] - The basic earnings per share for Q3 2024 was CNY 0.0186, reflecting a decline of 85.16% year-on-year[2] - The total comprehensive income for the third quarter of 2024 was CNY 82,005,458.65, compared to CNY 378,940,379.10 in the same period of 2023[18] - The basic and diluted earnings per share for the third quarter were CNY 0.0801, down from CNY 0.3887 year-over-year[18] - The company reported a decrease in sales revenue from CNY 3,753,093,132.51 in the first three quarters of 2023 to CNY 3,453,792,570.76 in 2024[19] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2024 was negative CNY 140,985,583.04, a decrease of 297.22% compared to the same period last year[2] - Cash flow from operating activities for the first three quarters of 2024 was CNY 3,591,159,885.43, a decrease from CNY 3,906,059,891.43 in the same period of 2023[20] - The net cash flow from operating activities was negative CNY 311,007,746.02, compared to negative CNY 9,639,629.08 in the previous year[20] - Cash flow from investing activities resulted in a net outflow of CNY 320,564,958.49, compared to a net outflow of CNY 362,607,590.84 in the same period of 2023[21] - Cash flow from financing activities showed a net outflow of CNY 239,236,006.80, contrasting with a net inflow of CNY 486,425,293.41 in the previous year[21] - The ending cash and cash equivalents balance was CNY 618,549,872.24, down from CNY 990,410,353.26 at the end of the previous year[21] - The company's cash and cash equivalents as of September 30, 2024, were approximately ¥621.99 million, down from ¥1,492.96 million at the end of 2023[12] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to CNY 8,985,674,710.63, an increase of 0.44% compared to the end of the previous year[3] - The company's total assets as of the end of the third quarter of 2024 were CNY 8,985,674,710.63, slightly up from CNY 8,946,377,928.42 at the end of 2023[15] - Total liabilities increased to CNY 2,495,124,825.05 from CNY 2,405,562,765.96 year-over-year, indicating a rise in financial obligations[15] - The company's equity attributable to shareholders decreased to CNY 5,485,792,742.43 from CNY 5,520,675,866.70, reflecting changes in retained earnings[15] - The equity attributable to shareholders at the end of Q3 2024 was CNY 5,485,792,742.43, a decrease of 0.63% from the previous year[3] Shareholder Information - The total number of common shareholders at the end of the reporting period was 39,022[8] - The largest shareholder, China Animal Husbandry Group Co., Ltd., holds 504,094,163 shares, accounting for 49.37% of total shares[10] - The total number of preferred shareholders with restored voting rights was 0[8] - The company has no pledged, marked, or frozen shares among its top shareholders[10] Operational Metrics - Accounts receivable at the end of Q3 2024 increased by 78.16%, primarily due to an increase in receivables within the payment period[7] - Short-term borrowings at the end of Q3 2024 increased by 57.01%, mainly due to additional short-term financing loans from banks[7] - The company reported a significant increase in prepayments to approximately ¥175.96 million from ¥58.14 million[13] - Inventory decreased slightly to approximately ¥1.06 billion from ¥1.09 billion[13] - The company's long-term equity investments amounted to approximately ¥803.11 million, up from ¥784.41 million[13] - The total current assets were approximately ¥3.81 billion, a slight decrease from ¥3.82 billion[13] Research and Development - Research and development expenses for the first three quarters of 2024 amounted to CNY 92,602,407.24, compared to CNY 84,150,995.12 in the same period of 2023, indicating a focus on innovation[17] Operating Costs - Total operating costs increased to CNY 4,125,409,573.52 from CNY 3,896,103,089.65 year-over-year, reflecting a rise in operating expenses[16] - Sales expenses for the first three quarters of 2024 were CNY 298,701,505.68, up from CNY 253,476,751.90 in the previous year, suggesting increased marketing efforts[16]

股票代码：600195 股票简称：中牧股份 编号：临 2024-046 中牧实业股份有限公司关于选举董事长的公告 中牧实业股份有限公司董事会 2024 年 10 月 18 日 附简历： 吴冬荀，男，59 岁，中国国籍，无境外永久居留权，大学本科学历，毕业于 中国农业大学，高级兽医师。曾任北京市朝阳区畜牧局技术员、北京华罗饲料添加 剂厂销售员、车间主任、海安分厂厂长；中牧实业股份有限公司供销公司业务二部 经理、湖北中牧安达药业有限公司总经理、中牧实业股份有限公司生物制品事业部 副总经理、生物制品商务部总经理；中牧实业股份有限公司总经理助理兼生物制品 商务部总经理、副总经理兼生物制品事业二部总经理、副总经理兼生物制品事业部 总经理。2017 年至今，任中牧实业股份有限公司董事、总经理。 吴冬荀先生持有公司股份 157,438 股，与持有公司 5%以上股份的股东、实际控 制人、其他董事、监事及高级管理人员之间不存在关联关系，未受过中国证监会及 其他有关部门的处罚和证券交易所的惩戒。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...